Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine by unknown
1 3
Med Microbiol Immunol (2015) 204:57–68
DOI 10.1007/s00430-014-0374-x
REVIEW
Enhanced immune response to hepatitis B vaccination 
through immunization with a Pre‑S1/Pre‑S2/S Vaccine
Daniel Shouval · Hedwig Roggendorf · 
Michael Roggendorf 
Received: 21 June 2014 / Accepted: 26 September 2014 / Published online: 4 January 2015 
© The Author(s) 2014. This article is published with open access at Springerlink.com
Recently, it has been suggested that such Pre-S/S vaccines 
against HBV might be efficacious not only for prevention 
but also for intervention in persistent HBV infection. Data 
obtained in a recent clinical trial conducted in Vietnam in 
patients with chronic hepatitis B suggest that repeated 
monthly i.m. injections of the Sci-B-Vac™ co-administered 
with daily oral lamivudine treatment can suppress HBV rep-
lication and lead to anti-HBs seroconversion in ~50 % of 
treated patients. Optimization of protocols and efficacy of 
such an intervention, intended to bypass T cell exhaustion 
and immune tolerance to HBV remains to be explored.
Keywords Prevention of hepatitis B · Recombinant HBV 
vaccines · Immunogenicity · Sci-B-Vac™ · Pre-S1/Pre-
S2/S · Hepatitis B vaccine
Abbreviations
Anti-HBs  Antibodies to HBsAg
ALT  Alanine amino transferase
BMT  Bone marrow transplantation
cccHBV-DNA  Covalently closed circular HBV-DNA
CHB  Chronic hepatitis B
CHO  Chinese hamster ovary cells
DHFR  Dihydrofolate reductase
ESRD  End stage renal disease
HBIG  Hepatitis B immune globulin
HBV  Hepatitis B virus
HBcAg  Hepatitis B core antigen
HBeAg  Hepatitis B e antigen
HBsAg  Hepatitis B surface antigen
ITT  Intention to treat analysis
LAM  Lamivudine
LHBs  Large hepatitis B surface antigen (Pre-S1)
NUCS  Nucleos(t)ide analogues
mIU  Milli International Units
Abstract Efficacy and safety of recombinant yeast-
derived hepatitis B vaccines for prevention of hepatitis 
B have been demonstrated unequivocally worldwide as 
reflected in reduction in HBsAg carrier rates and hepato-
cellular carcinoma. A new generation of recombinant HBV 
vaccines expressed in mammalian cells containing Pre-S/S 
epitopes has been developed in several countries. Such vac-
cines are useful in special risk groups, i.e., in non-respond-
ers to conventional HBV vaccines including older adults, 
obese people, health care workers, patients with renal fail-
ure and on dialysis, transplant patients, patients with HIV as 
well as travelers on short notice to HBV endemic regions. 
The future of such vaccines depends on their enhanced 
immunogenicity and cost profile. Sci-B-Vac™ is a mam-
malian cell-derived recombinant Pre-S1/Pre-S2/S hepa-
titis B vaccine which has been shown to be highly immu-
nogenic, inducing faster and higher seroprotection rates 
against HBV with higher anti-HBs levels at lower HBsAg 
doses as compared to conventional yeast-derived vaccines. 
This article is part of the special issue “Therapeutic vaccination 
in chronic hepatitis B—approaches, problems, and new 
perspectives”.
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MHBs  Middle hepatitis B surface antigen (Pre-S2)
SHBs  Small hepatitis B surface antigen (S)
VAC  Vaccine
History of hepatitis B vaccines
First-generation, plasma-derived hepatitis B vaccines were 
developed in the US and France in the late 1970s. In the 
mid 1980s, second-generation recombinant DNA hepati-
tis B vaccines were constructed in yeasts transfected with 
HBV-DNA sequences coding for the small hepatitis B 
virus (HBV) surface protein (SHBs). These vaccines have 
gradually replaced the first-generation plasma-derived vac-
cines and are currently used for universal vaccination of 
newborns and adults in >170 countries worldwide [1–3]. 
Third-generation HBV vaccines containing one (Pre-S2) or 
two (Pre-S1 and Pre-S2) additional HBV envelope proteins 
have been developed in Germany, France, Korea and Israel 
in transfected mammalian cells [2, 4–6], Table 1 (see also 
article from W. Gerlich in this issue).
Non‑response to conventional hepatitis B vaccines 
and the rationale for development of a more 
immunogenic Pre‑S/S hepatitis B vaccine
Successful seroprotection against HBV infection is defined 
by rate and by an anti-HBs titer of ≥10 mIU/ml following 
immunization or following resolution of HBV infection 
with the wild-type virus. Administration of three doses of 
licensed HBV vaccines to healthy subjects usually elicits an 
anti-HBs titer which is much higher than the defined sero-
protection threshold of 10 mIU/ml and may reach several 
hundred to thousands of anti-HBs units. However, despite 
the extraordinary efficacy of second-generation HBV vac-
cines, immunization failure may occur and can sometimes 
be explained by variables such as improper storage, intra-
gluteal injection, advanced age, obesity, renal failure, HIV 
infection, celiac disease, diabetes mellitus, chronic liver 
disease, inflammatory conditions such as Crohn’s disease, 
cancer and especially, immunosuppression [7–17]. Another 
important factor that may affect non-responsiveness to 
SHBs immunization seems to be genetically determined 
resistance [18, 19]. The ability to produce anti-HBs anti-
bodies in response to immunization with the hepatitis B 
surface antigen (HBsAg) is controlled by autosomal domi-
nantly expressed HLA Class II molecules. Milich et al. fol-
lowed by Shouval et al. [6, 20] have shown in mice that 
non-responsiveness to immunization with small HBsAg 
(SHB) can be circumvented through immunization with 
Pre-S envelope proteins. Furthermore, immunization with 
synthetic middle Pre-S2 HBV peptide (MHBs) as well as 
with yeast and mammalian CHO cell-derived Pre-S2 vac-
cines may induce neutralizing antibodies and protect chim-
panzees against HBV challenge [21]. Yet, initial experience 
in humans, using second-generation yeast-derived HBV 
vaccines containing mixtures of Pre-S and S antigens, did 
not lead to clinical application of such vaccines [22, 23]. 
Regardless of the initial fallback of Pre-S/S vaccines, there 
was and still is a justification for using more immunogenic 
vaccines that are efficacious in specific risk groups of non-
responders or low responders to conventional HBV vacci-
nation [24]. Such populations include genetic or advanced 




 Contain non-glycosylated p24 and glycosylated gp27, gp33, gp36
c
 Contain non-glycosylated p24 and p39, and glycosylated gp27, gp33, gp36, gp42
Vaccine type Manufacturer Envelope antigen Remarks
Plasma derived Hepatavax-B® (Merck & Co.) SHBs HBsAg, 5–40 μg/dose, licensed worldwide (not in use)
Hevac B® (Pasteur M., France) SHBsAg, (± MHBs) HBsAg, 5–20 μg/dose, licensed in France (not in use)
KGC® (Korea Green Cross) SHBsa HBsAg, licensed in East Asia
Recombinant, yeast 
derived
RECOMBIVAX® HB (Merck & Co.,  
USA)
SHBsa HBsAg, small S, 2.5–10 μg/dose, licensed worldwide
Engerix-B® (GSK, Belgium) SHBsa HBsAg, small S, 10–20 μg/dose, licensed worldwide




Gen Hevac B® (Pasteur M, France)b SHBs, MHBs HBsAg (S, Pre-S2), 20 μg/dose, licensed in France
Sci-B-Vac/Bio-Hep-B™/Hepimmune™ 
(SciVac, Israel)c
SHBs, MHBs, LHBs HBsAg, small S, Pre-S1, Pre-S2, 2.5–10 μg/dose, 
licensed in Israel and several countries in East Asia
AG-3™ (Hepagene™) (Medeva, UK)c SHBs, MHBs, LHBs HBsAg, small S, Pre-S1, Pre-S2, 10–20 μg/dose, (not 
manufactured anymore)
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age-associated non-responders to yeast-derived vaccines 
(i.e., health care workers at risk, contacts of HBsAg car-
riers, newborns to HBsAg carrier mothers), patients with 
chronic liver disease or after liver transplantation, HIV 
patients, intravenous drug users, patients with chronic 
renal failure and on dialysis and other immunosuppressed 
patients. It was suggested that immunization with such 
Pre-S1/Pre-S2/S HBV vaccines may also reduce the risk of 
emerging of S gene mutants [25, 26].
The development of a triple Pre‑S1/Pre‑S2/S hepatitis B 
vaccine
Pre-clinical studies
Sci-B-Vac™ is an aluminum hydroxide adjuvanted recom-
binant hepatitis B vaccine, currently manufactured by Sci-
Vac Israel Ltd. The Pre-S1/Pre-S2/S vaccine was origi-
nally developed at the Weizmann Institute of Science, the 
Hadassah Medical Center and Biotechnology General in 
Israel. It was previously manufactured under the trade 
names Bio-Hep-B™ or Hepimmune™. It is produced in 
mammalian Chinese hamster ovary (CHO) cells, trans-
fected with appropriate sequences that code for the HBV 
envelope proteins—the small S hepatitis B surface antigen 
(SHBs), the middle Pre-S2 (MHBs) and the large Pre-S1 
envelope protein (LHBs) [27]. The gene coding for these 
antigens, including the native HBs promoter, enhancer and 
polyA signal, was cloned into a plasmid vector containing 
the mouse dihydrofolate reductase (DHFR) expression cas-
sette. The plasmid was used to establish the producer CHO 
cell line. Transfected cells were selected for DHFR+ phe-
notype, and gene co-amplification was done with metho-
trexate. SDS-PAGE analysis of the purified HBs particles, 
which are of the adw2 subtype, secreted by the transfected 
CHO cells, revealed the presence of all three hepatitis sur-
face antigens in non-glycosylated and glycosylated forms, 
mainly the SHBs (75–77 % p24, gp27), the MHBs (17–
21 % gp33, gp36) and the LHBs (3–7 % p39, gp42) [6]. 
The presence of Pre-S2 and Pre-S1 antigens in the final vac-
cine preparation was confirmed in BALB/c mice and rab-
bits, which develop appropriate anti-Pre-S1 and anti-Pre-S2 
antibodies following immunization with Sci-B-Vac™ [6]. 
The development of anti-Pre-S1 and anti-Pre-S2 antibod-
ies and their relationship to anti-HBs levels were later also 
documented in immunized children [28–30]. The physical 
properties of the HBV envelope particles produced in CHO 
cells and the immune response to HBV Pre-S/S envelope 
proteins have been characterized in details [31, 32].
Comparative immunization studies in BALB/c mice 
revealed that the third-generation Pre-S1/Pre-S2/S vac-
cine has an extraordinary immunogenicity manifested by 
significantly higher seroconversion rates and higher anti-
HBs titers in immune-competent animals immunized with 
Sci-B-Vac™, as compared to yeast-derived recombinant 
HBsAg vaccines such as H-B-Vax® and Engerix-B® [6]. 
Furthermore, the threshold immunogenic dose in 50 % of 
mice at day 14 after primary immunization was 0.13 μg 
for Sci-B-Vac™ and over sixfold higher for the other two 
yeast-derived control vaccines. Finally, and most impor-
tantly, mice of the strain B/10 M, which are genetically 
non-responsive to SHBs and MHBs antigens at the T cell 
level, were able to seroconvert following immunization 
with Sci-B-Vac™, with 100-fold higher anti-HBs titers as 
compared to conventional recombinant yeast-derived vac-
cines [6]. These results indicated that the CHO-derived 
vaccine elicits an augmented anti-HBs response in mice, as 
compared to yeast-derived vaccines, and is able to circum-
vent genetic resistance to small HBs.
Clinical studies
To date, over 20 clinical studies have been completed in 
>3,000 patients immunized with Sci-B-Vac™ with an 
excellent safety record, including healthy adults, children 
and neonates [28–30, 33–39]. Additional ongoing studies 
are in progress in patients on hemodialysis and patients 
with HIV. In Israel, the Pre-S1/Pre-S2/S vaccine is in rou-
tine use for universal vaccination given on date of birth to 
~50 % of all neonates (approximately 300,000 doses per 
year). The remaining 50 % of neonates currently receive 
Engerix-B®. Vaccine is usually administered at 0, 1 and 
6 months, and formulations in alum hydroxide include 2.5 
or 5 μg/injection of the envelope antigens for children up to 
10 years old in non-endemic and endemic regions for HBV, 
respectively; 10 μg/injection for children >10 years of age 
and healthy adults and 20 μg/injection for immune-sup-
pressed patients, patients on dialysis and for non-respond-
ers to conventional yeast-derived HBV vaccines.
In a pilot study conducted in medical students in Israel, 
the seroprotection rate defined as an anti-HBs titer of 
≥10 mIU/ml following a single 10 μg dose of the Pre-S/S 
vaccine was already 70 % (mean anti-HBs titer of 81 mIU/
ml) as measured at 6 months post-priming as compared 
to 25 % in the yeast-derived vaccinees immunized with 
20 μg SHBs (mean anti-HBs titer of 12 mIU/ml), Fig. 1 
[37]. After one booster injection at 6 months, 100 % sero-
protection was achieved in all groups with anti-HBs levels 
rising 356-fold to 28,800 mIU/ml and 77-fold to 923 mIU/
ml in recipients of Sci-B-Vac™ and Engerix-B®, respec-
tively (P < 0.025). A second injection of Engerix-B® at 
1 month in addition to the 6 month booster was required 
to reach similar anti-HBs levels for both groups of vac-
cinees at 7 months. From the early studies and onwards, 
it became evident that in comparison with yeast-derived 
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HBV vaccines, >50 % of vaccinees (neonates, children and 
young adults) receiving Sci-B-Vac™ develop earlier sero-
protection against HBV already within 4 weeks of a single 
(priming) dose.
A mathematical model was constructed to assess the 
pace and impact of anti-HBs production on immune mem-
ory following vaccination [40]. Wilson et al. collected data 
from 15 clinical trials, 14 of which monitored immune 
response to first-generation (plasma-derived) and second-
generation (yeast-derived) HBV vaccines as well as trials 
conducted in recipients of third-generation vaccines, i.e., 
Sci-B-Vac™. The model predicts that third-generation 
Pre-S-containing vaccines induce immunity to HBV as 
early as 1–2 weeks from priming compared to the average 
6–7 weeks in recipients of second-generation vaccines such 
as Engerix-B®, Recombivax® or Heberbiovac®.
The rapid immune response to Sci-B-Vac™ was cor-
roborated by Schumann et al. [41] who recorded a fast and 
efficient cellular- and humoral-specific immune response 
against the envelope protein(s) of HBV using lymphocyte 
proliferation and Elispot assays which develops within a 
few weeks following the priming immunization.
Several phase 2 and phase 3 studies were conducted in 
adults, children and neonates in Israel, Singapore, Vietnam, 
Philippines, Thailand and Poland [2, 28, 33–36, 38]. A few 
examples describing the main results of some of the studies 
are summarized as follows:
The enhanced immunogenicity induced through immu-
nization with Sci-B-Vac™ was documented in a group of 
105 young adults in Israel who reached 97 and 98 % sero-
protection rates at month 6, following two injections of 5 
or 10 μg/dose at 0 and 1 month, respectively. At month 7, 
1 month after administration of a third injection, seropro-
tection rates were 100 % for both 5 and 10 μg doses, reach-
ing an anti-HBs peak level of 12,177 and 14,998 mIU/
ml, respectively. Thus, a mammalian cell-derived Pre-S/S 
vaccine dose of 5 μg was sufficient to induce an excellent 
humoral immune response, Fig. 2.
In another study, conducted in neonates in Vietnam, a 
dose response relationship could be demonstrated using 
low doses of the Pre-S/S vaccine. More vaccinees who 
received the 5 µg dose/injection had anti-HBs titers ranging 
from 1,001 to 10,000 mIU/ml as compared to those who 
received the 2.5 µg dose/injection. More than 50 % of the 
vaccinees in the 5 µg dose group developed these high titers 
within 3 months after the third vaccination, Fig. 3. Further-
more, in study, HBN-014-01-2, 98.9 % had already pro-
tective anti-HBs titers at month 6 (following two vaccine 
doses) rising to 100 % at month 9, 3 months after injection 
of the third vaccine dose.
Cumulative data obtained during comparative immuno-
genicity studies were evaluated in larger cohorts containing 
populations from Israel as well as East Asia. On pooling 
data from two studies conducted in Singapore and Israel 
(protocols HBA 9006-S; 38-96-40), which compared the 
10 μg Sci-B-Vac™ dose to the 20 μg Engerix-B® dose, 
the initial seroconversion rates at month 1 were signifi-
cantly higher in the Sci-B-Vac™ group (67 %) than in the 
Engerix-B® group (19 %). GMT levels were significantly 
higher for Sci-B-Vac™ than Engerix-B® throughout the 
studies and peaked [5,999 mIU/ml for Sci-B-Vac™ and 
2,056 mIU/ml for Engerix-B® (P = 0.001)] at 1 month fol-
lowing the third injection, respectively.
In comparative controlled studies conducted in Israel, 
more than 50 % of adult vaccinees who received the 10 µg/
dose and neonates who received the 2.5 µg/dose had anti-
HBs titers 100–10,000 mIU/ml after the third vaccination 
Fig. 1  Rapid seroprotection against hepatitis B following the first 
dose of a Pre-S1/Pre-S2/S vaccine. Comparison of seroprotection 
(%), after one and two doses of 10 μg/1.0 ml of Sci-B-Vac (n = 10; 
shaded bars) and 20 μg/ml Engerix-B® (n = 8; white bars). Arrows 
reflect time of immunization. Reproduced by permission from Ref. 
[37]
Fig. 2  Anti-HBs response expressed as geometric mean titers (GMT), 
following immunization of vaccine and HBV naïve individuals with a 
Pre-S1/Pre-S2/S hepatitis B vaccine. Vaccinees (n = 105), 18–29 years 
old, M/F ratio 1:3, received three i.m. injections of Sci-B-Vac™ (V) at 
5 or 10 μg/dose at 0,1 and 6 months. Seroprotection rates at 2, 6, 7 and 
12 months post-priming were in the range of 79–83, 97–98, 100 and 
100 %, respectively, for both groups. Quantitative anti-HBs response is 
expressed in mIU/ml. Modified, based on Ref. [35]
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(Fig. 3). These rates were higher than those observed in 
vaccinees who received the yeast-derived control vac-
cines Engerix-B® and Hepavac II®. Furthermore, no 
non-responders were observed in immunized neonates 
who received 2.5 µg Sci-B-Vac™. In adults, the number 
of non-responders who received Sci-B-Vac™ was small 
(3.5 %, 18/513) as compared to vaccinees immunized with 
Engerix-B® (13.7 %, 43/415).
The enhanced immunogenicity of the Pre‑S1/Pre‑S2/S 
vaccine in specific risk groups
Patients with renal failure
Twenty-nine patients with end stage renal disease (ESRD) 
who did not respond in the past to repeated immuniza-
tion with a double dose of a second-generation HBV vac-
cination protocol received 10 µg of Sci-B-Vac™ vaccine 
intramuscularly at 0, 1 and 6 months. Following immu-
nization, 25/29 patients (86 %) developed seroprotective 
anti-HBs levels. In comparison, retrospective evaluation 
of the seroconversion rates in the same study center dur-
ing the previous 3 years showed that only 19/36 (56.4 %) 
ESRD patients seroconverted using repeated immuniza-
tion with a yeast-derived HBV vaccine [39]. This enhanced 
response was also expressed in a significantly higher titer 
of anti-HBs antibodies observed in the Sci-B-Vac™ cohort 
immunized with one-fourth of the HBsAg dose as com-
pared to historical controls vaccinated with 40 µg/dose of 
yeast-derived HBsAg. The results of this pilot study require 
confirmation through a controlled comparative study which 
is due to start shortly.
Non-responders to immunization with conventional 
yeast-derived HBV vaccines
A multicenter randomized comparative immunogenicity 
study of the Pre-S1/Pre-S2/S hepatitis B vaccine was con-
ducted in eight European and Israeli centers [42]. The study 
population consisted of 716 individuals previously diag-
nosed as non-responders, mean age 50 years old, divided 
into two sub-cohorts of non-responders to 3 or 4 doses of 
a yeast-derived vaccine (anti-HBs titers <10 mIU/ml) and 
low responders to a conventional vaccination protocol 
(anti-HBs titer <100 mIU/ml). Study participants classified 
as non-responders or low responders received a first dose 
of Sci-B-Vac™ at 20 μg on day 0. If the elicited anti-HBs 
titer at day 36 ± 7 was <100 mIU/ml, participants received 
a second booster on day 85 ± 7. Engerix-B®, at a dose 
of 20 μg/injection, was used as a control vaccine. In the 
primary study population (non-responders after ≥4 previ-
ous injections, ITT analysis) at 1 month after the first or 
second injection, the proportion of vaccinees with anti-HBs 
titers of ≥100 IU/l was higher for those injected with Sci-
B-Vac™ (35.7 %) as compared to the conventional control 
vaccine (20.8 %; P = 0.006). Using the threshold for sero-
protection of ≥10 mIU/ml anti-HBs, the results showed an 
even higher response rate for the Pre-S1/Pre-S2/S vaccine 
as compared with the S vaccine (81.7 and 49.1 %, respec-
tively; P < 0.001). These data which included HLA typing 
confirmed the initial observation in non-responder mice 
that genetically determined non-response to conventional 
yeast-derived HBV vaccines can be partially overcome 
through immunization with a mammalian cell-derived tri-
ple antigen Pre-S1/Pre-S2/S vaccine. Thus, the study by 
Rendi-Wagner et al. [42] established that two injections of 
this third-generation vaccine to be superior to conventional 
vaccines in inducing relatively high (≥100 IU/l) anti-HBs 
antibody titers in both non-responders and low responders 
to previous conventional vaccination. Furthermore, it also 
confirmed the preliminary observation from Singapore 
regarding effectiveness of this vaccine in non-responders to 
first-generation, plasma-derived HBV vaccines [43].
Patients with overweight
Increased body weight is one of a number of factors asso-
ciated with reduced immunogenicity of HBV vaccines. 
Figure 4 demonstrates the effect of weight on quantita-
tive anti-HBs levels in adult vaccinees in studies 38-92-
001 and 38-96-040. In these comparative controlled trials, 
increased body weight was associated with a decrease in 
seroprotection rates in recipients of yeast-derived vaccines. 
Fig. 3  Distribution of anti-HBs titers in anti-HBc (-), HBsAg (-) neo-
nates, immunized at birth and at 1 and 6 months, who received either 
2.5 μg/0.5 ml, (N = 495;  dark blue bars) or 5 μg/0.5 ml, (N = 200; 
light blue bars) Sci-B-Vac™/dose, data recorded at month 9 post-
priming. (Data extracted from registration file, study HBN014-01)
62 Med Microbiol Immunol (2015) 204:57–68
1 3
In contrast, the impact of overweight on anti-HBs levels 
was practically neutralized in adults immunized with three 
doses of Sci-B-Vac™ at 10 µg/dose as compared to recipi-
ents of a yeast-derived vaccine Engerix-B® who received a 
20 µg/injection, twice the dose of Sci-B-Vac™ (P < 0.012), 
Fig. 4. These data confirm a similar observation from Japan 
where high weight Sumo wrestlers responded more favora-
bly to a Pre-S2/S HBV vaccine as compared to a conven-
tional yeast-derived S-containing vaccine (Yamada K et al. 
Hepatology Research 1998; 12:3, abs).
Immune-suppressed patients
The enhanced immunogenicity of the Pre-S1/Pre-S2/S 
HBV vaccine under conditions of immune suppression was 
demonstrated in a number of settings. In a study by Lo and 
co-workers from Hong-Kong, 20 patients who underwent 
liver transplantation for chronic HBV infection treated 
with lamivudine, but not with hepatitis B immune globulin 
(HBIG), received two courses each of three double doses 
(20 µg) of Sci-B-Vac™ at a median of 637 days after trans-
plantation [44]. Five patients (25 %) responded to the first 
vaccination course and five additional patients responded 
after the second course with an overall response rate of 
50 %. The response rate was 88 % in patients <50 years old 
and 25 % in older patients (P = 0.02). The median peak 
anti-HBs titer was 153 mIU/ml with six responders having 
a titer >100 mIU/ml and seven had a sustained response 
>6 months. Among seven previous non-responders to sec-
ond-generation recombinant vaccine, 3 (44 %) responded. 
In conclusion, immunization with Sci-B-Vac™ was effec-
tive in about 50 % of immunosuppressed, HBV-infected 
liver transplant patients receiving lamivudine prophy-
laxis without HBIG.
A similar experience was recently reported from Ger-
many where an obese 40-year-old pregnant woman devel-
oped fulminant hepatitis and underwent liver transplantation 
[45]. The patient was treated with lamivudine and HBIG 
and 3 years after transplantation was immunized with five 
doses of Sci-B-Vac™ at an 1–2 week interval without an 
adequate anti-HBs response. Three months later, she was 
re-vaccinated with three additional doses of the Pre-S1/
Pre-S2/S vaccine which led to anti-HBs seroconversion. 
Once HBV-specific lymphocyte proliferation reached a 
stimulation index of 8.7, with a corresponding HBV-specific 
enzyme-linked immunosorbent spot assay response, HBIG 
treatment was withdrawn, 3 months after initiation of vac-
cination. Anti-HBs titer remained >700 mIU/ml for at least 
6 months. These results provide further support to the con-
clusion that the Pre-S1/Pre-S2/S HBV vaccine can break 
tolerance to HBV envelope proteins even under conditions 
of heavy immune suppression induced by combined treat-
ment of tacrolimus, mycophenolate mofetil and prednisone.
Further support for the enhanced immunogenicity of the 
Pre-S/S HBV vaccine was demonstrated by our group in 
irradiated, immune-suppressed BALB/c mice transplanted 
with bone marrow (BMT) from matched donor mice, 
immunized with 1 μg of either Sci-B-Vac™ or a yeast-
derived HBV vaccine i.p. [46]. BMT recipient mice devel-
oped protective anti-HBs titers within days of BMT from 
immunized donors [46]. Moreover, BMT recipient mice 
from Pre-S1/Pre-S2/S-immunized donors developed sig-
nificantly higher anti-HBs titers as compared to mice trans-
planted with bone marrow obtained from mice immunized 
with a yeast-derived control HBV vaccine (D. Shouval, 
unpublished results), Fig. 5.
The ability to induce protective anti-HBs antibody levels 
in immune-suppressed organ transplant recipients through 
adoptive transfer of immunity was further confirmed in 
other animal models such as rats and woodchucks [47, 48].
Indeed, active transfer of humoral and cellular immu-
nity through adoptive transfer of immunity to HBV was 
also repeatedly demonstrated in HBV naïve human BMT 
recipients transplanted with immune cells from a vacci-
nated donor as well as in BMT recipients with persistent 
HBV infection transplanted with an HBV immune bone 
marrow [46, 49–52]. In a pioneering study, Schumann 
et al. [53] immunized 14 potential live liver donors with 
repeated double doses of Sci-B-Vac™ and followed the 
development of cellular and humoral immunity in their 
liver transplant recipient. Adoptive transfer of cellular and/
or humoral immunity to HBsAg was demonstrated in three 
liver transplant recipients by lymphocyte proliferation and 
Elispot assays as well as by conventional anti-HBs immu-
noassay. The intensity of the humoral immune response 
in liver transplant recipients was proportional to the anti-
HBs levels generated in donors through immunization with 
Fig. 4  Effect of body weight on immunogenicity. Comparison of 
GMT (anti-HBs titers) in adults who received three doses of either 
Sci-B-Vac™ (Bio-Hep-B™) or Engerix-B® at 0, 1 and 6 months 
(studies 38-92-001 and 38-96-040), measured at month 7). Repro-
duced from the registration file of Sci-B-Vac™ in Israel
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Sci-B-Vac™. These investigators have also shown a simi-
lar phenomenon in liver transplant patients with persistent 
HBV infection who received a liver lobe from an immu-
nized donor with temporal clearance of circulating, periph-
eral HBV-DNA.
Prospects of Sci‑B‑Vac™ as a therapeutic vaccine
Currently available anti-viral agents against persistent 
HBV infection include interferon alpha as well as nucleo-
tide and nucleoside analogues (NUCS). Only a minority 
of preselected patients reach a sustained response to inter-
feron. NUCs are quite effective in suppression of viraemia 
and intra-hepatic viral replication but have no direct impact 
on intra-nuclear, covalently closed circular cccHBV-DNA 
which can persist for years and serves as template for the 
transcription of HBV pregenomic RNA [54]. It remains to 
be seen if the recent detection of sodium taurocholate co-
transporting polypeptide identified as the HBV receptor 
[55] will lead to development of more efficient anti-viral 
agents which support elimination of cccHBV-DNA by pre-
venting infection of new hepatocytes [56].
Most patients persistently infected with HBV are either 
immunotolerant or immunologically hyporesponsive, dis-
playing a weak cellular and altered cytokine immune 
responses to viral nucleocapsid and envelope antigens [57]. 
During the past 15 years, repeated attempts have been 
made to develop immunologic and pharmacologic means to 
resolve the well described immunologic hyporesponsiveness 
and T cell exhaustion to HBV proteins in such patients [57]. 
These include among others repeated immunization with 
conventional S vaccines and development of more immu-
nogenic vaccines such as Pre-S2/S [5, 58, 59], Pre-S1/Pre-
S2/S vaccines [3, 6], vaccines containing HBsAg-anti-HBs 
immune complexes [60, 61], lipopeptide-based vaccines [62] 
and DNA vaccines [63]. Furthermore, other means for stim-
ulating an enhanced immune response against HBV include 
development of new adjuvants with improved immune stim-
ulation as compared to the conventional aluminum hydrox-
ide used in most vaccines or using an intradermal route for 
vaccine administration (reviewed in [24, 26, 64–70]). The 
use of conventional or modified HBV vaccines for interven-
tion in persistent infection (in contrast to prevention) has 
been termed “therapeutic vaccination” intended to restore 
dysfunctional immune and in particular T cell responses. 
Cumulative data collected during the past decade suggest 
that the utility of such immunologic maneuvers has met with 
limited success [65]. For example, already in 1994, Pol et al. 
[71] have conducted a pilot study immunizing HBsAg car-
riers with the mammalian cell-derived Pre-S2/S HBV vac-
cine GenHevac B® and observed a ~50 % reduction in viral 
replication. However, a randomized controlled trial in recipi-
ents of 20 μg/dose GenHevac B®, and two control groups 
receiving either yeast-derived Recombivax® or no treatment 
did not confirm the initial observations [5]. Yet, HBV-DNA 
“negativization” rates were somewhat higher in the Pre-S2/S 
vaccine recipient (15 %) as compared to the control group 
(2.7 %), but this effect was not sustained following cessa-
tion of vaccination. Regardless of several failures in using 
GenHevac B® as a therapeutic vaccine [5, 72], these inves-
tigators could demonstrate a specific CD4 T cell response 
against viral envelope epitopes in some of the vaccinees [58]. 
A similar observation was reported from Japan where Ren 
et al. [73] evaluated a transfected hepatoma cell line-derived 
product containing glycosylated and non-glycosylated SHBs 
with a small amount of MHBs. Combining SHBs with 
more potent adjuvants than alum hydroxide such as AS02 
[74] or immunization with HBsAg-anti-HBs immune com-
plexes [75] did not prove so far to be significantly effective 
in clearing persistent HBV infection. Results obtained in 
some of these studies suggest that success of immunother-
apy through vaccination may be inversely proportional to the 
degree of viral load. Consequently, effective suppression of 
viral load before or at least at initiation of vaccinotherapy 
seems logical. Boni et al. [76] have shown that high concen-
tration of HBV antigens can disrupt T cell functions which 
can be restored in vitro through suppression of viral load by 
NUCs such as lamivudine or entecavir. Indeed, lamivudine 
treatment can restore immunologic hyporesponsiveness in 
patients with chronic hepatitis B (CHB) through enhance-
ment of a CD4-mediated response to nucleocapsid antigens 
within 4–7 days of treatment initiation [77]. However, such 
stimulation and restoration of T cell reactivity seem to be 
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Fig. 5  Adoptive transfer of immunity to HBV in mice: anti-HBs 
response in immune-suppressed BALB/c mice (N = 10), treated 
by whole body irradiation and bone marrow transplantation from 
immune-competent donor mice immunized i.p. with 1 μg of HBsAg 
(D. Shouval, unpublished data)
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transient. Therefore, immune stimulation of the hyporespon-
sive HBV-specific T cells through therapeutic vaccination 
should be initiated early after initiation of anti-viral treat-
ment with lamivudine [78].
A few years ago, an attempt was made to assess the 
immunomodulatory impact of oral administration of 
HBsAg on the cellular and humoral immune response 
against HBV surface proteins [79]. Feeding of mice with 
HBV surface antigens followed by immunization with 
the Pre-S/S HBV vaccine BioHep B lead to significant 
suppression of anti-HBs antibody levels. The investiga-
tors concluded that oral tolerance induction effectively 
down-regulated pre-existing immunity and reduced the 
anti-HBs titers in previously immunized mice to 112 ver-
sus 223 mIU/ml, in tolerized compared with non-tolerized 
controls (P < 0.01). These results obtained in mice are dif-
ficult to reconcile with data obtained in a follow-up non-
controlled study in humans who received oral treatment 
with Sci-B-Vac™ (without aluminum hydroxide). Feeding 
42 patients with persistent HBV infection was associated 
with a 26 % HBeAg seroconversion rate during a 20-week 
follow-up period with a decrease in viral load in 36 % of 
recipients. This effect was also reported to be associated 
with augmentation of HBsAg-specific T cell proliferation, 
interferon gamma positive T cell clones and natural killer 
T cell activity in >50 % of patients [80]. These results con-
tradict the current understanding of the immunopathology 
of persistent HBV infection and require confirmation using 
adequate controls including groups to be fed with placebo 
as well as with HBcAg. Until then, the implications of 
these results as such are open to different interpretations.
Previous observations suggest that conventional and Pre-
S2/S HBV recombinant HBV vaccines may induce some 
suppression of viral load in patients with persistent HBV 
infection which seems more effective in the presence of 
low-level viraemia. Based on the cumulative experience, 
Hoa et al. evaluated the potential of using Sci-B-Vac™ as a 
therapeutic vaccine in patients with CHB. In this controlled 
clinical trial conducted in Vietnam between 2003 and 2006, 
180 HBsAg+/HBeAg+ CHB patients, 16–70 years old, 
were randomized to receive 8 monthly i.m. doses of Sci-B-
Vac™ 20 μg/dose alone (VAC), 8 monthly i.m. injections 
of Sci-B-Vac™ 20 μg/dose in combination with 100 mg 
lamivudine daily (VAC + LAM) or monotherapy with 
lamivudine 100 mg/day (LAM). Fourteen patients discon-
tinued treatment prematurely. The main results of this study 
include:
1. Significant suppression of median viral load from 
an overall base line of ~106 log copies/ml by at least 
1 log copy/ml was observed at 3 months for the 
VAC + LAM and the LAM treatment groups being 
maximal for the combination group at a 65 % response 
rate (median reduction of viral load 2.6 log copies/ml) 
as compared to 55 % in the LAM group (1.9 log cop-
ies/ml) and 18.3 % (1 log copies/ml) in the VAC group, 
Fig. 6. Furthermore, an overall rate of HBV-DNA 
suppression <4 log copies/ml was observed in 55 % 
of the VAC + LAM group as compared to 28.3 % in 
the monotherapy with LAM. This effect was sustained 
and still present at month 12, 4 months after adminis-
tration of the last vaccine dose. These results suggest 
that co-administration of Sci-B-Vac™ and lamivudine 
have a synergistic effect on suppression of viral load 
as compared to vaccination alone or monotherapy with 
lamivudine. At month 18 post-initiation of treatment, 
viral load suppression was still documented in 51.7 and 
43.4 % of VAC + LAM and LAM recipients, respec-
tively. Yet, from the data presented, it seems that the 
enhanced viral suppression afforded by administration 
of Sci-B-Vac™ in the combination group was wan-
ing at month 18, when patients were off treatment for 
10 months.
2. At month 18, 10 month after cessation of treatment, 
seroconversion rates to anti-HBs ≥10 mIU/ml were 
observed in 51.7 % of the combination group, in 
31.7 % of recipients of vaccine alone and in none of 
the lamivudine recipients. Vaccine-induced anti-HBs 
responses ≥10 mIU/ml were already documented at 
month 9, 1 month after the last vaccine dose in both 
the VAC and VAC + LAM recipients at 21.7 and 35 %, 
respectively, rising to 28.3 and 45 % at month 12, 
respectively. Furthermore, at month 12, 4 months after 
the last vaccine injection, anti-HBs levels between 100 
and 1,000 mIU/ml were documented in 49 % of all 
vaccine recipients regardless of study group, Table 2.
3. HBsAg loss was documented in only one patient in the 
VAC group, in two patients in the VAC + LAM recipi-
ents and in one LAM treated patient. HBeAg loss was 
Fig. 6  HBV-DNA reductions at 3 months post-treatment. The per-
centage of patients with early HBV-DNA reduction (after 3 months) 
was expressed using two cutoff levels (reductions of >1 log copy/ml 
and >2 log copies/ml). The asterisk indicates a significant difference 
between the VAC + LAM and LAM groups (P < 0.05). VAC-recipi-
ents of Sci-B-Vac™, V + L-recipients of Sci-B-Vac™ and Lamivu-
dine, LAM recipients of lamivudine. Reproduced by permission Ref. 
[81]
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similar in all three treatment arms ranging between 
21 and 33 % at month 18. Sero-reversion to HBeAg 
positivity was documented at the end of the observa-
tion period in 6.7 and 5.0 % of VAC + LAM and LAM 
recipients, respectively. Biochemical response defined 
as alanine amino transferase (ALT) reduction to <1.5 
upper limit of normal levels was reported for 63, 67 
and 78 % of VAC, VAC + LAM and LAM recipients, 
respectively, P non-significant.
4. Although a more detailed description of the safety fol-
low-up is not presented in the report of Hoa et al. [81], 
the authors state that they did not observe any serious 
adverse events or hepatitis flares during the study period.
Analysis of the data of the clinical trial conducted by 
Hoa et al. [71] suggest that, as previously observed with 
another PreS-2/S vaccine, such vaccines are able to induce 
some suppression of viral load through a yet unknown 
mechanism, an effect which as shown in the present study, 
can be augmented by NUCS, i.e., lamivudine. Furthermore, 
co-administration of Sci-B-Vac™ with lamivudine lead to 
an unprecedented anti-HBs seroconversion rate of about 
50 % which seem to contribute to the control of persistent 
infection as also reflected in improvement of markers for 
hepatocellular injury. These data therefore suggest that 
despite previous doubts regarding the ability of aluminum 
adjuvanted vaccines to restore the immunologic T cell-asso-
ciated hyporesponsiveness, repeated immunization with a 
highly immunogenic Pre-S1/Pre-S2/S vaccine can bypass 
immune tolerance at least in some patients. However, the 
study protocol and results had a number of limitations and 
several issues regarding the utilization of Sci-B-Vac™ and 
co-administration with a nucleos(t)ide analogue for vac-
cinotherapy require further study. Further information is 
required regarding the durability of anti-HBs levels with 
precise quantitative anti-HBs and HBV-DNA monitoring 
under treatment. Use of more potent NUCs than lamivu-
dine as well as assessment of intra-hepatic cccDNA and the 
requirement for further vaccine booster injections should 
also be assessed. Further studies are also required regarding 
the monitoring of the adoptive and innate immune response 
in responders and non-responders to vaccinotherapy.
Since the discovery of HBsAg as a hepatitis-associ-
ated antigen in 1968 [82], eradication of persistent HBV 
infection has been an elusive goal. The definition of cure 
has changed over the past decades as it became clear that 
suppression of viral replication, HBeAg seroconversion 
and even HBsAg seroconversion to anti-HBs are not suf-
ficient to clear the intra-hepatic cccHBV-DNA and prevent 
dividing hepatocytes from new HBV infection [54]. Con-
sequently, the goal of clearing persistent HBV infection 
was put at least temporarily on “hold” while immunologic 
control of HBV appeared a more achievable target. Indeed, 
repeated injections with a highly immunogenic Pre-S1/Pre-
S2/S vaccine seem to induce an 18 months sustainable anti-
HBs response with corresponding partial control of circu-
lating HBV-DNA.
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